Review of Recommended Treatment of Uterine Carcinosarcoma.

about

Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study.Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma.

P2860

Q37512369-E87E4EDE-C664-466A-BEAE-044675A8381E Q41218661-0894BABF-8D50-46B3-8D4E-07F6024DCDD6

P2860

Review of Recommended Treatment of Uterine Carcinosarcoma.

Item

http://www.wikidata.org/entity/Q38587635

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Review of Recommended Treatment of Uterine Carcinosarcoma.

@en

type

Item

label

Review of Recommended Treatment of Uterine Carcinosarcoma.

@en

prefLabel

Review of Recommended Treatment of Uterine Carcinosarcoma.

@en

P1476

Review of Recommended Treatment of Uterine Carcinosarcoma.

@en

P2093

Joseph Menczer

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant treatment modalities, prognostic predictors and outcomes of uterine carcinosarcomas

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.

A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.

PDGFR-alpha as a potential therapeutic target in uterine sarcomas.

Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).

Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.

Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.

A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.

Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.

P2888

s11864-015-0370-4

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11864-015-0370-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1036155635

http://www.w3.org/2001/XMLSchema#string

P698

26374341

http://www.w3.org/2001/XMLSchema#string

Review of Recommended Treatment of Uterine Carcinosarcoma.

about

P2860

P2860

Review of Recommended Treatment of Uterine Carcinosarcoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698